Kenji Morishima - Santen Pharmaceutical Director
| SNPHY Stock | USD 10.61 0.39 3.55% |
Director
Kenji Morishima is Executive Officer, Chief Director of Human Resources & Organization Development and CSR of Santen Pharmaceutical Co since 2018.
| Tenure | 6 years |
| Phone | 81 6 7664 8621 |
| Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Graham Chipchase | AstraZeneca PLC ADR | 54 | |
| Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
| Frans Houten | Novartis AG ADR | 61 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Nancy Andrews | Novartis AG ADR | 63 | |
| Phyllis Yale | Bristol Myers Squibb | 63 | |
| Simon Moroney | Novartis AG ADR | 62 | |
| Ann Fudge | Novartis AG ADR | 70 | |
| Michel Demare | AstraZeneca PLC ADR | 62 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Philip Broadley | AstraZeneca PLC ADR | 52 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
| Gerald Storch | Bristol Myers Squibb | 64 | |
Management Performance
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 |
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satoshi Suzuki, Executive Officer, Chief Director of Planning | ||
| Nobuko Kato, Chief Officer | ||
| Mika Masunari, G Officer | ||
| Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | ||
| Nikolas Tripodis, Chief Officer | ||
| Kaori Itagaki, Gen Group | ||
| Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | ||
| Shinichi Teramachi, Head Officer | ||
| Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | ||
| Ippei Kurihara, Japan Department | ||
| Minori Hara, Chief Officer |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | 14.22 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santen Pink Sheet Analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.